Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Increase in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 66,900 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Ratings Changes

A number of research analysts have commented on the company. HC Wainwright increased their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler began coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price objective for the company.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR traded up $3.19 during mid-day trading on Monday, hitting $32.94. The company had a trading volume of 13,869 shares, compared to its average volume of 360,329. The stock has a market cap of $200.97 million, a price-to-earnings ratio of -16.72 and a beta of 1.18. The firm’s 50 day simple moving average is $35.77 and its two-hundred day simple moving average is $21.54. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC increased its stake in Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after buying an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $2,861,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $3,694,000. Finally, RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.